Compare Amylx Pharmaceuticals Inc (AMLX) vs Dover Corp (DOV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Dover Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Dover Corp trades at $214.05 (market cap $29.00B). The key difference: Dover Corp is far larger — about 14.6× Amylx Pharmaceuticals Inc's market cap, and Dover Corp pays a 0.97% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | DOV | |
|---|---|---|
Market Cap | $1.98B | $29.00B |
Sector | Health | Industrials |
52-Week High | $18.70 | $233.31 |
52-Week Low | $7.64 | $161.16 |
Enterprise Value | $1.70B | $30.64B |
Dividend Yield | — | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Dover Corporation (DOV) trades at $215.33, up 1.78% today, with a bearish technical signal but strong fundamentals including a 13.3% net income margin and consistent earnings beats. Recent news highlights product launches in data center and industrial solutions, supporting revenue growth. The stock is supported by a high analyst buy consensus and a $251 price target, though technical indicators show resistance near $214.
Outlook is positive with robust profitability and analyst optimism, but risks include market volatility and execution challenges. The stock offers value through earnings growth and dividend yield, with upside potential if it breaks resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →
